
https://www.science.org/content/blog-post/bill-ackman-pompey-and-you
# Article Title (April 2017)

## 1. SUMMARY

This article analyzes the collapse of Valeant Pharmaceuticals and its largest investor, billionaire hedge fund manager Bill Ackman, who lost at least $3 billion on the investment. The author uses this case as a prime example of overconfidence and the sunk-cost fallacy, drawing parallels to how Pompey dealt with Julius Caesar according to Montesquieu—slowly yielding to reality while repeatedly denying the impending danger.

The article argues that pharmaceutical and biotechnology investments make investors particularly vulnerable to narrative-driven thinking. Investors get so "invested" in the stories behind companies that they follow them "right over the cliff." Valeant's appeal to Ackman wasn't the typical drug development story but rather a more sophisticated business narrative: that Valeant had cracked the code on pharmaceutical profitability through hard-nosed cost-cutting and business acumen, unlike the "slow and old-fashioned" traditional drug industry that relied on messy clinical luck.

The piece concludes by noting how humans naturally convert complex situations into coherent stories with beginnings, middles, and clear winners/losers—a cognitive bias that affects both investing and research projects. The article ends cynically noting that Valeant's new turnaround CEO was paid $62 million despite the company's ongoing struggles.

## 2. HISTORY

**Valeant's Continued Decline and Transformation:**
Valeant Pharmaceuticals never recovered from its collapse. The company faced multiple crises beyond just its business model: massive debt burden (over $30 billion at its peak), numerous lawsuits, federal investigations, and allegations of fraudulent accounting practices. Under new CEO Joseph Papa (the $62 million compensation referenced in the article), the company attempted a turnaround strategy that involved selling assets and focusing on core therapeutic areas.

In 2018, Valeant changed its name to Bausch Health Companies, attempting to distance itself from the toxic Valeant brand. The company divested numerous assets, including selling its skincare subsidiary Obagi Medical Products and its iNova Pharmaceuticals unit. Despite these efforts, the company continued to struggle under its massive debt load.

**Bill Ackman's Aftermath:**
Ackman's Pershing Square fund lost approximately $4 billion on Valeant—one of the worst investments in hedge fund history. However, Pershing Square survived and went on to make successful investments in other sectors. Notably, Ackman later made billions during the COVID-19 pandemic through timely investments and trades, though the Valeant debacle remained a cautionary tale that he referenced in investor communications.

**Broader Industry Impact:**
Valeant's collapse and the scrutiny it brought did lead to some regulatory attention and increased skepticism toward pharmaceutical companies that pursued aggressive acquisition and price-hiking strategies without meaningful R&D investment. However, the core business model Valeant represented—acquiring existing drugs and dramatically increasing prices—became less viable due to public outcry and political pressure.

The article's warnings about narrative-driven investing proved prescient, as numerous other biotech and pharma companies with compelling "stories" but weak fundamentals continued to attract investor enthusiasm and subsequent disappointment.

## 3. PREDICTIONS

• **"Valeant's story will be a terrific example for years to come of overconfidence and the sunk-cost fallacy"** - **ACCURATE**: Valeant did become one of the most-cited case studies in business schools and investment circles for cognitive biases in investing, alongside other famous failures like Enron and Theranos.

• **Implied prediction that Valeant wouldn't successfully turn around under the new CEO despite his massive compensation** - **ACCURATE**: Valeant never recovered to anything resembling its former valuation or business model. The company's transformation/rebranding to Bausch Health represented a fundamental retreat from Valeant's aggressive strategy, and shareholder value was largely destroyed.

• **General caution about narrative-driven investing in pharma/biotech** - **ACCURATE**: The pattern continued and arguably intensified, with numerous biotech companies achieving massive valuations based on compelling scientific narratives that later collapsed when clinical or commercial realities emerged (see various CAR-T, gene therapy, and Alzheimer's drug failures in subsequent years).

• **Implication that investors holding Valeant stock were fundamentally different from rational actors** - **PARTIALLY ACCURATE**: Most rational investors did exit Valeant with substantial losses, while the remaining long-term shareholders did indeed prove to be either stubbornly optimistic or trapped by tax considerations, though some value investors did eventually find opportunities in the restructured company.

## 4. INTEREST

**Rating: 7/10**

This article demonstrates strong analytical insight into the cognitive psychology behind investment failures, using a timely and significant case study. While focused on a specific company collapse, its observations about narrative-driven thinking apply broadly to biotech/pharma investing and remain relevant as similar patterns continue to emerge in the sector.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20170403-bill-ackman-pompey-and-you.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_